AlphAIAlphAI — Financial news for AI agents
prnewswire.comNOV 12 min read$ABT

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.

Original reporting
prnewswire.com
Published Nov 1, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 1, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System — source image
Source · prnewswire.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The data were presented at the TCT conference and published in JACC: Cardiovascular Interventions, marking the first public disclosure of these results.

02

Market read

First report of successful trial outcomes could drive near‑term stock movement and long‑term valuation uplift.

03

What to watch

Potential competition from other IVL technologies and reimbursement uncertainties.

Relevance 9/10Novelty 9/10Timing: today

Background

Abbott's SonicForce system is an investigational coronary IVL device designed to treat heavily calcified lesions.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott announced positive 30‑day results from its investigational SonicForce IVL system, meeting safety and effectiveness endpoints.

Expected impact

likely upward pressure as investors price in potential approval and market share gains

Evidence & confidence

The trial met primary endpoints with 0.3% target lesion failure and 97% procedural success, a strong signal for regulatory clearance.

Market effects

Sector

May accelerate adoption of intravascular lithotripsy in the cardiovascular device sector.

Regional

U.S. medical device market could see increased investor interest.

Global

Potentially influences global coronary intervention technologies and competitor pipelines.

Counterpoint

What could challenge this read

Regulatory approval is not guaranteed; trial success may not translate to market adoption.

Key entities

  • Company
    Abbott Laboratories

    Developer of the SonicForce IVL system.

  • Product
    SonicForce™ Coronary IVL System

    Investigational device evaluated in the TECTONIC study.

Read at source← All news

StoryAbbott reports strong 30‑day safety and efficacy results for investigational SonicForce IVL system

Also covered by

1 outlet

Related articles

NOV 2
$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

finance.yahoo.com2 min
NOV 2
$ABTMedAI 8/10

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

stocktitan.net2 min
NOV 2
$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.

prnewswire.com2 min
NOV 1
$ABTMedAI 8/10

Scans found heart-artery calcium fractures after an investigational sound-wave treatment

Abbott's investigational SonicForce Coronary IVL System showed positive results in the TECTONIC study, meeting safety and effectiveness endpoints. The study enrolled 335 patients with severe coronary calcification, reporting a 0.3% 30-day target lesion failure rate and 97% procedural success. The system uses acoustic pressure waves to crack calcium buildup in coronary arteries, potentially expanding Abbott's cardiovascular portfolio.

stocktitan.net2 min
OCT 31
$AVGOMed

Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

Analysts made notable calls this week. D.A. Davidson upgraded Broadcom (AVGO) to Buy with a $400 price target, citing AI-related growth prospects. William Blair downgraded Moderna (MRNA) to Market Perform due to valuation concerns. Argus downgraded Abbott (ABT) to Hold after its reduced growth outlook. Jefferies upgraded Rivian (RIVN) to Buy, citing progress in margins and execution. GF Securities raised AMD's (AMD) price target to $720, expecting strong data center growth.

tradingview.com2 min